Accueil   Agenda - News   Toutes les news A disruptive technology to produce an innovative antimicrobial treatment for Cystic Fibrosis

A disruptive technology to produce an innovative antimicrobial treatment for Cystic Fibrosis

 

 

Lyon (France), 24 January 2019 – A strategic milestone of the project ALX-009 has now been completed: Lyon-based biotech company Alaxia announces the start of production of its innovative device dedicated to the extemporaneous production of its drug candidate ALX-009. In an incredible timeframe, Alaxia has overcome the challenge of developing an intuitive and fully automated portable device. The production is now running since early January 2019. This innovative device was a must to give independent access to ALX-009 to patients, indeed it has been designed to allow full secure use by patients at home or by healthcare professionals. This will facilitate the pharmaceutical and clinical development of ALX-009.

 

Lire le communiqué de presse

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer